TY - JOUR
T1 - Combined medication and cognitive therapy for generalized anxiety disorder
AU - Crits-Christoph, Paul
AU - Newman, Michelle G.
AU - Rickels, Karl
AU - Gallop, Robert
AU - Gibbons, Mary Beth Connolly
AU - Hamilton, Jessica L.
AU - Ring-Kurtz, Sarah
AU - Pastva, Amy M.
N1 - Funding Information:
This research was supported by National Institute of Mental Health (NIMH) grant R34-MH072678 . The parent study was supported by NIMH grant R01-065963 . Wyeth Laboratories provided study medications for the parent study. The authors report no financial involvement or affiliation with any organization whose financial interests may be affected by material in this article.
PY - 2011/12
Y1 - 2011/12
N2 - The current study assessed efficacy of combined cognitive behavioral therapy (CBT) and venlafaxine XR compared to venlafaxine XR alone in the treatment of generalized anxiety disorder (GAD) within settings where medication is typically offered as the treatment for this disorder. Patients with DSM-IV-diagnosed GAD who were recently enrolled in a long-term venlafaxine XR study were randomly offered (n= 77), or not offered (n= 40), the option of adding 12 sessions of CBT. Of those offered CBT, 33% (n= 26) accepted and attended at least one treatment session. There were no differences between the combined treatment group and the medication only group on primary or secondary efficacy measures in any of the sample comparisons. Many patients who present in medical/psychopharmacology settings seeking treatment for GAD decline the opportunity to receive adjunctive treatment. Of those that receive CBT, there appears to be no additional benefit of combined treatment compared to venlafaxine XR alone.
AB - The current study assessed efficacy of combined cognitive behavioral therapy (CBT) and venlafaxine XR compared to venlafaxine XR alone in the treatment of generalized anxiety disorder (GAD) within settings where medication is typically offered as the treatment for this disorder. Patients with DSM-IV-diagnosed GAD who were recently enrolled in a long-term venlafaxine XR study were randomly offered (n= 77), or not offered (n= 40), the option of adding 12 sessions of CBT. Of those offered CBT, 33% (n= 26) accepted and attended at least one treatment session. There were no differences between the combined treatment group and the medication only group on primary or secondary efficacy measures in any of the sample comparisons. Many patients who present in medical/psychopharmacology settings seeking treatment for GAD decline the opportunity to receive adjunctive treatment. Of those that receive CBT, there appears to be no additional benefit of combined treatment compared to venlafaxine XR alone.
UR - http://www.scopus.com/inward/record.url?scp=81155160972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81155160972&partnerID=8YFLogxK
U2 - 10.1016/j.janxdis.2011.07.007
DO - 10.1016/j.janxdis.2011.07.007
M3 - Article
C2 - 21840164
AN - SCOPUS:81155160972
SN - 0887-6185
VL - 25
SP - 1087
EP - 1094
JO - Journal of Anxiety Disorders
JF - Journal of Anxiety Disorders
IS - 8
ER -
